CAMBRIDGE, MA / ACCESS Newswire / October 22, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the Company’s ...
Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min While Moderna downplayed the ...
Findings showed the study did not meet its primary endpoint of preventing CMV infection in seronegative participants. Topline results were announced from a phase 3 study evaluating Moderna’s ...
ADVERTISEMENT Barrie Watch CMV’s pulled from road by police Multiple commercial vehicles have been removed from the road – with drivers facing charges following an enforcement blitz.
Moderna plans to continue evaluating mRNA-1647 in an ongoing Phase 2 trial for bone marrow transplant patients, where the vaccine could potentially suppress disease associated with CMV reactivation.
Abstract: The conventional reduced-common-mode-voltage model predictive control (RCMV-MPC) faces the challenges of low control accuracy and high switching frequency at low speeds. To reduce CMV, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback